8-K: Allogene Therapeutics Announces Positive Clinical Trial Results and Provides Corporate Update

Allogene Therapeutics reported third quarter 2024 financial results and provided a business update, highlighting progress in its allogeneic CAR T cell therapy programs.

Summary

• Allogene Therapeutics announced its third quarter 2024 financial results and provided a corporate update on November 7, 2024.
• The company is advancing its pivotal Phase 2 ALPHA3 trial for cema-cel in large B-cell lymphoma, with enrollment expected to complete in the first half of 2026 and primary efficacy data by the end of 2026.
• A potential biologics license application (BLA) submission for cema-cel is targeted for 2027.
• Pre-clinical data for ALLO-329, a dual CAR T therapy for autoimmune diseases, will be presented at the American College of Rheumatology meeting in November 2024, with an IND application targeted for Q1 2025 and proof-of-concept data expected by the end of 2025.
• Positive Phase 1 data for ALLO-316 in renal cell carcinoma was presented, showing a 50% overall response rate and a 33% confirmed response rate in patients with a CD70 tumor proportion score greater than 50%.
• The company ended Q3 2024 with $403.4 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2026.
• Research and development expenses for the third quarter were $44.7 million, while general and administrative expenses were $16.3 million.
• The net loss for the third quarter was $66.3 million, or $0.32 per share.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results and a clear path forward for several programs, but also includes some negative safety data and financial losses. The RMAT designation and cash runway are positive indicators, but the risks associated with clinical development temper the overall sentiment.

Positives

• The ALPHA3 trial is the first pivotal trial to offer CAR T as part of first-line treatment consolidation for large B-cell lymphoma.
• ALLO-329 is the first allogeneic CD19/CD70 dual CAR T product specifically designed for autoimmune diseases.
• ALLO-316 demonstrated a manageable safety profile with a newly implemented diagnostic and management algorithm appearing effective in abating IEC-HS.
• The RMAT designation for ALLO-316 highlights its potential to address unmet needs in advanced renal cell carcinoma.
• The company's cash runway is projected into the second half of 2026, providing financial stability for ongoing research and development.

Negatives

• The company reported a net loss of $66.3 million for the third quarter of 2024.
• Three Grade 5 treatment-related adverse events were reported in the ALLO-316 trial, including cardiogenic shock, sepsis, and failure to thrive.
• Two dose limiting toxicity (DLT) events of autoimmune hepatitis and cardiogenic shock were reported in the ALLO-316 trial.

Risks

• The company's novel technology carries potential adverse effects.
• There are risks associated with the success, cost, and timing of product development activities and clinical trials.
• The regulatory approval process is uncertain and may lead to delays.
• There are potential delays or difficulties in product manufacturing.
• The company faces competition from other biopharmaceutical companies.
• Obtaining additional funding to develop product candidates and implement operating plans is a risk.
• General economic and market conditions could impact the company's performance.

Future Outlook

The company expects its cash runway to fund operations into the second half of 2026 and anticipates a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024. GAAP Operating Expenses are expected to be approximately $300 million, including estimated non-cash stock-based compensation expense of approximately $60 million. The company is targeting a potential BLA submission for cema-cel in 2027 and an IND application for ALLO-329 in Q1 2025.

Management Comments

• We are proud of the progress made in the third quarter of 2024 to advance our investigational allogeneic cell products in key firsts, said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.
• We believe these efforts have the potential to redefine treatment paradigms, tailoring therapies to meet the unique needs of large patient populations and enabling broader real-world adoption.
• Allogene remains dedicated to driving innovation that improves outcomes for patients with both cancer and autoimmune diseases.

Industry Context

Allogene is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T cell therapies, which are designed to be off-the-shelf products, potentially offering advantages over autologous CAR T therapies that require patient-specific manufacturing. The company's focus on both cancer and autoimmune diseases positions it to address significant unmet medical needs. The RMAT designation for ALLO-316 is a positive signal for its potential in the competitive landscape of cancer therapeutics.

Comparison to Industry Standards

• The 50% overall response rate and 33% confirmed response rate for ALLO-316 in renal cell carcinoma are promising compared to historical outcomes with standard therapies in heavily pretreated patients.
• Autologous CAR T therapies have shown efficacy in hematological malignancies, but Allogene's allogeneic approach aims to overcome limitations such as manufacturing time and patient-specific requirements.
• Companies like Gilead (Kite Pharma) and Novartis are leaders in autologous CAR T therapy, while Allogene is focused on the allogeneic space, which could offer broader accessibility and scalability.
• The development of dual CAR T therapies like ALLO-329 for autoimmune diseases is an emerging area, with few direct comparators, making Allogene's approach innovative.

Related Party Transactions

• Collaboration revenue of $22 was reported from a related party.

Stakeholder Impact

• Shareholders may react positively to the clinical trial progress and RMAT designation, but negatively to the reported net loss.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with cancer and autoimmune diseases may benefit from the development of new treatment options.
• Suppliers and creditors may view the company's financial position as stable.

Next Steps

• Continue site activation and patient screening/enrollment for the ALPHA3 trial.
• Present pre-clinical data for ALLO-329 at the American College of Rheumatology meeting.
• File an IND application for ALLO-329 in Q1 2025.
• Continue the Phase 1 TRAVERSE trial for ALLO-316.
• Prepare for a potential BLA submission for cema-cel in 2027.

Key Dates

Keywords

Allogene, CAR T, Cell Therapy, Lymphoma, Autoimmune Disease, Renal Cell Carcinoma, Clinical Trial, RMAT, Biotechnology, Oncology